Captrust Financial Advisors Cuts Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Captrust Financial Advisors reduced its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 23.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,421 shares of the medical research company's stock after selling 1,951 shares during the quarter. Captrust Financial Advisors' holdings in Charles River Laboratories International were worth $1,185,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of CRL. Fiduciary Financial Group LLC raised its position in shares of Charles River Laboratories International by 3.9% during the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock worth $310,000 after acquiring an additional 63 shares during the last quarter. Pinnacle Bancorp Inc. grew its stake in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after acquiring an additional 65 shares during the period. Cornerstone Investment Partners LLC lifted its holdings in shares of Charles River Laboratories International by 3.7% in the fourth quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company's stock valued at $358,000 after purchasing an additional 69 shares in the last quarter. Metis Global Partners LLC lifted its holdings in shares of Charles River Laboratories International by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company's stock valued at $318,000 after purchasing an additional 72 shares in the last quarter. Finally, Two Sigma Securities LLC lifted its holdings in shares of Charles River Laboratories International by 4.3% in the fourth quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock valued at $366,000 after purchasing an additional 81 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the transaction, the executive vice president now directly owns 19,513 shares in the company, valued at $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Birgit Girshick bought 1,514 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average price of $164.63 per share, with a total value of $249,249.82. Following the completion of the transaction, the chief operating officer now owns 55,058 shares of the company's stock, valued at $9,064,198.54. This represents a 2.83% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders sold 5,040 shares of company stock worth $807,407. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Stock Performance

Shares of CRL traded up $2.11 during mid-day trading on Friday, hitting $141.00. The stock had a trading volume of 1,473,414 shares, compared to its average volume of 982,743. The firm has a market cap of $6.93 billion, a P/E ratio of 940.00, a PEG ratio of 4.54 and a beta of 1.50. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $254.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The business has a fifty day moving average price of $135.43 and a 200-day moving average price of $164.86.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.28. The company had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm's quarterly revenue was down 2.7% compared to the same quarter last year. During the same period in the previous year, the business earned $2.27 earnings per share. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their price target for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. JPMorgan Chase & Co. dropped their price target on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. Barclays lifted their price target on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a report on Thursday, May 8th. Mizuho dropped their price target on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. Finally, Evercore ISI upgraded Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price target on the stock in a report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, Charles River Laboratories International currently has an average rating of "Hold" and a consensus price target of $172.31.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).